NHS 'overcharged' by drug makers' non-compete deal, says CMA Two pharmaceutical firms have been accused of pushing up the price of a "lifesaving" NHS drug by striking a deal not to compete with each other.
The Competition and Markets Authority (CMA) said in provisional findings that Actavis and Concordia fixed the market for hydrocortisone tablets.
Hydrocortisone treats life-threatening conditions such as Addison's disease.
A pack of the tablets almost doubled in price for the NHS to £88 while the deal was in place, the CMA said. BBC News